Hope for rare sarcoma: drug showdown in metastatic ASPS
NCT ID NCT01391962
First seen Feb 02, 2026 · Last updated Jun 13, 2026 · Updated 24 times
Summary
This study tested two oral medications, sunitinib and cediranib, in 34 people with a rare and hard-to-treat cancer called alveolar soft part sarcoma (ASPS) that had spread. Participants were randomly assigned to one drug, and if their cancer worsened, they could switch to the other. The goal was to see if either drug could shrink tumors or slow the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA, ALVEOLAR SOFT PART are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.